Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next >>

Date	Time	Source	Headline	Symbol	Company
10/11/2023	8:30AM	PR Newswire (US)	AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis	NYSE:ABBV	AbbVie Inc
10/10/2023	8:45AM	PR Newswire (US)	AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023	NYSE:ABBV	AbbVie Inc
10/05/2023	8:53AM	Dow Jones News	AbbVie Exercises Right to Buy Biotech Mitokinin for Initial $110 Million	NYSE:ABBV	AbbVie Inc
10/05/2023	8:05AM	PR Newswire (US)	AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline	NYSE:ABBV	AbbVie Inc
10/04/2023	4:11PM	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ABBV	AbbVie Inc
10/04/2023	11:07AM	PR Newswire (US)	Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy	NYSE:ABBV	AbbVie Inc
10/04/2023	8:00AM	PR Newswire (US)	AbbVie to Host Third-Quarter 2023 Earnings Conference Call	NYSE:ABBV	AbbVie Inc
10/03/2023	7:00AM	PR Newswire (US)	Allergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field	NYSE:ABBV	AbbVie Inc
09/29/2023	8:15AM	Dow Jones News	AbbVie: Phase 3 Venetoclax/Dexamethasone Study Falls Short in Multiple Myeloma	NYSE:ABBV	AbbVie Inc
09/29/2023	7:15AM	PR Newswire (US)	AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma	NYSE:ABBV	AbbVie Inc
09/25/2023	8:50AM	Dow Jones News	AbbVie, Genmab Get Conditional Europe OK of Tepkinly Lymphoma Drug	NYSE:ABBV	AbbVie Inc
09/25/2023	7:45AM	PR Newswire (US)	AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma	NYSE:ABBV	AbbVie Inc
09/18/2023	9:59AM	Dow Jones News	AbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study	NYSE:ABBV	AbbVie Inc
09/18/2023	9:00AM	PR Newswire (US)	Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence	NYSE:ABBV	AbbVie Inc
09/14/2023	1:01PM	Dow Jones News	AbbVie Currently Up Six Consecutive Days, On Track for Longest Winning Streak Since March 2022 -- Data Talk	NYSE:ABBV	AbbVie Inc
09/13/2023	5:12PM	Dow Jones News	Harpoon Shares Drop 7.3% as AbbVie Declines License Option	NYSE:ABBV	AbbVie Inc
09/13/2023	4:55PM	Dow Jones News	Harpoon Therapeutics Says AbbVie Declines to Exercise License Option	NYSE:ABBV	AbbVie Inc
09/13/2023	11:00AM	PR Newswire (US)	AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"	NYSE:ABBV	AbbVie Inc
09/12/2023	8:30AM	PR Newswire (US)	AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease	NYSE:ABBV	AbbVie Inc
09/08/2023	11:23AM	PR Newswire (US)	AbbVie Declares Quarterly Dividend	NYSE:ABBV	AbbVie Inc
09/07/2023	7:00AM	GlobeNewswire Inc.	Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease	NYSE:ABBV	AbbVie Inc
09/06/2023	8:45AM	PR Newswire (US)	Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs	NYSE:ABBV	AbbVie Inc
09/06/2023	8:00AM	PR Newswire (US)	AbbVie to Present at the Morgan Stanley Healthcare Conference	NYSE:ABBV	AbbVie Inc
08/30/2023	9:00AM	PR Newswire (US)	Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)	NYSE:ABBV	AbbVie Inc
08/28/2023	9:50AM	Dow Jones News	AbbVie Seeks U.S., Europe OK for Skyrizi in Ulcerative Colitis	NYSE:ABBV	AbbVie Inc
08/28/2023	8:45AM	PR Newswire (US)	AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis	NYSE:ABBV	AbbVie Inc
08/24/2023	6:30AM	Finscreener.org	SCHD: Should You Buy the Schwab US Dividend Equity ETF for Its Dividend Yield?	NYSE:ABBV	AbbVie Inc
08/17/2023	2:00AM	PR Newswire (US)	AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults	NYSE:ABBV	AbbVie Inc
08/07/2023	1:10PM	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:ABBV	AbbVie Inc
08/01/2023	8:45AM	PR Newswire (US)	Allergan Aesthetics Announces First Ever JUVÉDERM® Day	NYSE:ABBV	AbbVie Inc